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Objective: Placenta accreta is one of the main obstetrical complications worldwide. The aim of this study
was to report the experience of managing placenta accreta with a 6% polidocanol solution sclerotherapy.
Materials and Methods: We selected patients between 37 weeks of gestation and 38 weeks of gestation,
diagnosed with placenta accreta, treated at the Maternal Perinatal Hospital “Monica Pretelini Saenz”,
Toluca, Mexico, during the period from November 2013 to August 2014. The surgical technique has two
steps: (1) fundic-arciform caesarean section followed by a 6% polidocanol sclerosing solution through a
6Fr neonatal feeding tube upon its reaching the placental bed; (2) total abdominal hysterectomy with
internal hypogastric artery ligation.
Results: Data were collected from 11 patients with a mean age of 33.9 years (range, 26e42 years) and
2.8± 0.6 days of hospitalization in the obstetrical intensive care unit. The majority of patients were
classified as having pregnancies at an advanced age. All women were multigravidas. Bleeding volume
exhibited a range between 2.5 L and 3 L without any case of neonatal death but one mother died because
of coagulopathy.
Conclusion: We conclude that the technique that we are reporting is feasible for implementation in
obstetric hospitals, with technical and economic feasibility.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Maternalmortality inMexico remainshigh,with anannual report
in 2009 of 1207 deaths and a maternal death rate (MDR) of 62.2/
100,000 live births. In 2011 the State ofMexico, Mexico, reported 131
deaths with an MDR of 50.2, which, following a linear prospective,
yields 98 projected deaths for the year 2015 with an MDR of 38.2,
falling short of the target of millennium development goals, which
established an MDR of 22/100,000 live births for 2015 [1].
The World Health Organization reports that there are 536,000
maternal deaths worldwide annually, of which 140,000 are caused09, Colonia Rancho Dolores,
a Zeron).
bstetrics & Gynecology. Publishedby obstetric hemorrhage, representing 25% of all maternal deaths,
and >50% of these take place in the first 24 hours postpartum [2]. In
the U.S., placenta accreta has become an increasingly important
contributor to repeated cesarean delivery morbidity [3]. In Mexico,
obstetric hemorrhage is the second leading cause of maternal
death, causing an MDR of 14.3 in 2008. Uterine sluggishness con-
tinues to comprise the leading cause of obstetric hemorrhage in
developing countries [4], followed by placenta accreta, which can
range from one case per 2510 patients up to one case per 533 pa-
tients [5]. In a 20-year study conducted between 1982 and 2002,
placenta accreta accounted for 39% of the causes of obstetric
hemorrhage [6].
The main risk factors identified for placenta accreta include age
(>30 years), multiparity, placenta previa with prior cesarean sec-
tion (35% of cases), placenta previa with a history of three or more
cesareans (67% of cases), history of curettage (18e60% of cases), aby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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retention, and antecedents of intraamniotic infection [6].
Placenta accreta may lead to massive obstetric hemorrhage and,
as a consequence, to coagulation disorders. The need for total
hysterectomy, especially when associated with placenta previa and
insertion in previous caesarean scars, can influence the risk of
surgical damage to ureters, bladder, and other neighboring pelvic
structures, as well as respiratory distress syndrome in adults, and
even maternal death. Blood loss during birth fluctuates between
3000mL and 5000mL, thus having an institutionwith a blood bank
is essential [7]. Fetal morbidity is affected by prematurity in up to
50e70% cases, mainly in emergencies.
Prenatal diagnosis of placenta accreta allows for a treatment
plan based on a multidisciplinary and individualized approach. The
twomost important decisions are time of pregnancy resolution and
whether radical or conservative management must be followed [8].
In the case of previous uterine surgery, the following study protocol
is started: color Doppler ultrasound, magnetic resonance imaging,
and cystoscopy.
The conservative decision is to leave the placenta in situ, with or
without the use of drugs for expulsion or reabsorption, such as
oxytocin or methotrexate. Sclerotherapy has been utilized since
1939 for the treatment of reticular veins or telangiectasias (veins
3 mm in diameter) and since 1944 for these mixed with air
(Tessari three-way tap technique), with an increasing number of
medical applications in diseases involving blood vessels of different
sizes.
In relation to the previously mentioned method, polidocanol
(hydropolyethoxydodecane) is a mixture of dextrose and sodium
chloride that acts as a sclerosing liquid detergent, causing vascular
damage by altering surface tension in endothelial cells. The foam
preparation increases the duration and the surface area of contact
between the sclerosant and the vein wall, producing effective
sclerosis (fibrosis) by endothelial destruction and exposure of
endothelial subsclerosing collagen fibers, activating the intrinsicFigure 1. (A) Fundic-arciform cesarean incision; (B) polidocanol inspathway of coagulation through factor XII and turning the vessel
into a fibrous cord. The foam has early recanalization rates of up to
32%, suggesting that the primary mode of action of these agents is
to promote thrombotic occlusion instead of producing permanent
damage to the vein wall. The aim of this study was to report the
experience of managing placenta accreta with polidocanol
sclerotherapy.
Materials and methods
This was a prospective and descriptive study. We used a
continuous collection method to select patients between 37 weeks
of gestation and 38 weeks of gestation, diagnosed with placenta
accreta by ultrasound, treated at the Maternal Perinatal Hospital
“Monica Pretelini Saenz”, Health Institute of the State of Mexico,
during the period from November 2013 to August 2014.
Surgical technique
First surgical procedure: Fundic-arciform caesarean section
The patient is in supine position and ready for a caesarean
section (C-section), with permeable transurethral catheter and
under regional anesthesia. A midline extended supraumbilical
incision is made about 10 cm above the umbilicus, habitual
dissection by planes is done, and an intentional macroscopic
exploration for bladder-invasive placenta is carried out when
entering the abdominal cavity. If the diagnosis is confirmed, a
fundic-arciform hysterectomy is performed on the infiltrated sur-
face (Figure 1A), extracting the fetus. Thereafter, an umbilical vein is
identified, phlebotomy is performed using a scalpel, and then this is
cannulated with a 6Fr neonatal feeding tube upon its reaching the
placental bed, with a prior 3-mL dilution of the polidocanol-type
sclerosing solution, and 10 mL of room air mixing for about 20
seconds (Figures 1B and 1C). This is then applied directly into the
vein through the tube previously placed in the umbilical vein.tillation; (C) tissular visualization after polidocanol instillation.
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formed in a single plane with continuous suturing utilizing
absorbable sutures.
Second surgical procedure: Total abdominal hysterectomy with
internal hypogastric artery ligation
The sacral promontory is identified on searching for bifurcation
of the iliac artery. Once this is palpable, the internal hypogastric
artery is identified and then a retroperitoneal incision with scalpel
is performed. The fat plane is dissected; the artery, ureter, and vein
are identified, moving the ureter laterally and externally. Dissection
begins of the periarterial soft tissue using a Lahey forceps (90)
with gentle mobilization to avoid tearing the artery and acute
bleeding. After dissection, and with the artery exposed, two spools
of silk or absorbable suture (number 0) are set in place for arterial
ligation, with the cephalic extreme knotted about 2 cm from the
bifurcation and separated 1 cm from the caudal extreme. The
procedure is repeated on the contralateral side (Figures 2A and 2B).
At the end, the retroperitoneum is closed using absorbable suture
000. Ligation of the hypogastric arteries is known to diminish
uteroplacental blood flow by up to 30%, decreasing the risk of the
sclerosing solution migrating into the systemic circulation,
ensuring the uteroplacental application. The next step is the uterine
artery ligation as habitually conducted, and with care to avoid
damaging the ureter. With ligation of these vascular structures that
supply the uterus to a great degree, the surgeon proceeds with the
gentle dissection of the vesicouterine fold, in some cases with
ligation of bleeding vessels with thin, absorbable suture (000) using
an electrocautery or harmonic scalpel to cauterize vascular struc-
tures. On noting a small bladder injury, we proceed to the perfor-
mance of primary closure on two planes with absorbable suture at
continuous points without anchoring these, as this produces
ischemia of bladder tissue, predisposing to necrosis of a segment of
the repair, in turn causing urine leakage with the consequent for-
mation of a vesicovaginal fistula.
Statistical analysis
Data analysis was performed using Excel (Microsoft, Redmond,
Washington, USA). Frequency distribution tables were constructed,
calculating measures of central trend and dispersion for quantita-
tive variables.
Ethics
Ethical clearance was granted by the Research Committee of the
Maternal Perinatal Hospital “Monica Pretelini Saenz” (code:Figure 2. (A) Uterine artery ligation; (217B500402015067), Toluca, Mexico, and followed the General
Health Research Law of Mexico and the Declaration of Helsinki
(Fortaleza, Brazil). All patients were asked to sign written informed
consent.
Results
During the study period, 274 obstetric patients were admitted to
the intensive care unit. Fifteen patients fulfilled the entry criteria
for this protocol, with four of these being discarded due to
incomplete medical information. Final data was collected from 11
patients with a mean age of 33.9 years (range, 26e42 years).
The majority of patients were classified as having pregnancies at
an advanced age. As recommended, all patients received prenatal
care, with a median number of three consultations. Regarding the
number of gestations, all were at least in the third pregnancy with a
minimum of two previous C-sections recorded. Regarding the his-
tory of abortions, less than half of the participants had experienced
this misfortune.
Of note is the fact that the 11 patients were submitted to glob-
ular package, fresh frozen plasma, and cryoprecipitate transfusions.
Bleeding volume ranged between 2.5 L and 3 L (Table 1). Therewere
no cases of neonatal death but one mother died due to
coagulopathy.
Discussion
There is limited data to guide optimal management of placenta
accreta. The existing literature is predominantly comprised of case
reports and retrospective studies based on reviews of medical re-
cords over a number of years in a single or in a small number of
tertiary-care institutions. Such studies have a number of limita-
tions, including limited generalization and a lack of statistical po-
wer [9].
Worldwide, the usual treatments are administration of metho-
trexate, embolization of the internal iliac vessels, and resection of
the affected uterine segment, use of uterine compression sutures,
and oversuturing of the placental bed [7]. In a review of 60 cases of
placenta accreta, partial removal of the placenta (n¼ 26), in situ
administration of methotrexate (n¼ 22), and uterine embolization
(n¼ 12) were the most common techniques employed. Treatment
failure occurred in 4/26, 5/22, and 3/12 of patients, respectively; 11/
60 women had serious infectious complications, 21/60 had signif-
icant vaginal bleeding, and 4/60 developed disseminated intra-
vascular coagulation. The percentage of hysterectomy was 20%. The
conclusion was that the use of methotrexate and embolization
generates uncertain results [10].B) vesicouterine pouch dissection.
Table 1
General characteristics of the patients.
Variable Case Mean± SD
1 2 3 4 5 6 7 8 9 10 11
Age (y) 33 37 42 35 36 26 30 32 30 35 37 33.9± 4.3
Gestations 4 4 6 3 3 3 4 4 5 3 3 3.8± 0.9
Vaginal deliveries 1 0 0 1 0 0 0 0 0 0 0 0.1± 0.4
Caesarean sections 2 2 3 2 2 2 3 3 3 2 2 2.3± 0.5
Curettage 0 1 2 1 1 1 0 0 0 0 0 0.5± 0.6
Surgery time (min) 90 100 120 100 90 120 150 100 120 100 130 110.9± 18.6
Anesthetic time (min) 40 35 35 35 30 30 30 35 35 35 35 34± 3
Bleeding (L) 2.5 3 2.5 2.5 2.5 3 3 2.5 3 3 3 2.7± 0.261
Globular package transfusions (units) 4 5 5 5 5 5 5 5 5 5 5 4.9± 0.3
Fresh frozen plasma (units) 2 3 3 3 3 3 3 3 3 3 3 2.9± 0.3
Cryoprecipitates (units) 1 2 2 2 2 2 2 2 2 2 2 1.9± 0.3
Hospitalization time (d) 5 7 7 7 5 5 5 6 8 5 5 5.9± 1.1
Days in the O-ICU 2 3 3 3 3 3 2 2 4 3 3 2.8± 0.6
SD¼ standard deviation; O-ICU¼ obstetrical intensive care unit.
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German Society of Phlebology include venous malformations, with
the known absolute contraindications of allergy to the sclerosing
agent, severe systemic disease, deep vein thrombosis, severe
generalized infection, permanent immobility and confinement to
bed, peripheral occlusive arterial disease (Stage III or IV), and
contraindications for chronic complications of diabetes, arterial
occlusive disease Stage II, asthma, patent foramen ovale and
thrombophilia, or hypercoagulable state with or without a history
of deep vein thrombosis [11].
Compared with other sclerosing agents, polidocanol offers a
wide safety margin against necrosis by extravasation. Its applica-
tion is painless and possesses an anesthetic effect. The accepted
safety dose for sclerotherapy is 2 mg/kg, and the suggested dose is
10e20 mL of 3% solution in large veins.
Matsuoka et al [12] studied cases involving stepwise treatment
versus intraaortic balloon occlusion (IAOB), and reported a blood
loss of between 840 mL and 1150 mL in the first, and of between
2400 mL and 5200 mL in the second. We propose that with our
technique, the bleeding is less than in the second option, but higher
than with the stepwise treatment.
Uterine artery embolization has been employed to treat
placenta previa plus placenta accreta in gestation in an attempt to
avoid C-section [13]. Duan et al [14] have published the amount of
blood loss and blood transfusion, and the surgical procedure time of
586± 355 mL, 422± 83 mL, and 65.5± 10.6 min, respectively, using
C-section combined with temporary IABO followed by uterine ar-
tery embolization for the management of placenta accreta. In this
same study, mean postoperative hospital stay, occlusion time, and
fetal radiation dosewere 5.5± 2.6 days, 22.4± 7.2min, and 4.2± 2.9
mGy, respectively. Evidently, with uterine artery embolization,
blood loss, blood transfusion, and surgical procedure times are
lower than with sclerotherapy with polidocanol, but the total days
of hospitalization were more than with the technique we are
reporting.
The most important fact observed in our study was the
decreased bleeding, explained mainly by the following factors: (1)
the sclerosing solution tends to form a fibrous cap around the
uteroplacental vascular bed; (2) limitation of vascular flow by two
large vessels supplying the uterus: hypogastric arteries and uterine
arteries; and (3) the uterus itself, with the pharmacological action
of oxytocin or other uterotonic drugs such as carbetocin.
Some pharmacological effects must be taken into account when
administering polidocanol. For example, hemoglobinuria has been
reported after its application in venous malformations, the inci-
dence of nonfatal allergic phenomena ranges from 0.01e0.91%, andthere is also a reversible negative inotropic effect, reducing atrio-
ventricular and intraventricular conduction in a dose-dependent
manner, resulting in hypotension and bradycardia, particularly
when combined with other local anesthetics [15]. The possibility of
“big bubble” microembolism associated with stroke, transient
ischemic attacks, and vision problems remains hypothetical, but
there are reports in publications of case series [16,17].
While a limitation of this report is the small number of cases, the
results are promising, especially when conservative management
of placenta accreta is not feasible [18].
We conclude that it is possible to implement our technique in
obstetric hospitals, with technical and economic feasibility. A
comparative study with other wide-domain techniques is
mandatory.
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